170229-04-6

Basic information

• Product Name: TERT-BUTYL 4,4-BIS(2-HYDROXYETHYL)PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4,4-BIS(2-HYDROXYETHYL)PIPERIDINE-1-CARBOXYLATE;tert-Butyl 4,4-bis(2-hydroxyethyl)-1-piperidinecarboxylate;1-Piperidinecarboxylic acid, 4,4-bis(2-hydroxyethyl)-, 1,1-diMethylethyl ester
• CAS NO: 170229-04-6
• Molecular Formula: C14H27NO4
• Molecular Weight: 273.37
• Mol File: 170229-04-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 392.2 °C at 760 mmHg
• Flash Point: 191 °C
• Appearance: /
• Density: 1.079
• CAS DataBase Reference: TERT-BUTYL 4,4-BIS(2-HYDROXYETHYL)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4,4-BIS(2-HYDROXYETHYL)PIPERIDINE-1-CARBOXYLATE(170229-04-6)
• EPA Substance Registry System: TERT-BUTYL 4,4-BIS(2-HYDROXYETHYL)PIPERIDINE-1-CARBOXYLATE(170229-04-6)

Safety Data

• Hazardous Substances Data: 170229-04-6(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL 4,4-BIS(2-HYDROXYETHYL)PIPERIDINE-1-CARBOXYLATE is a chemical compound commonly used as a hindered amine light stabilizer (HALS) in various applications, including polymers, coatings, and adhesives, to prevent degradation caused by UV radiation and heat. It is a highly effective antioxidant and UV stabilizer that helps to extend the lifespan and maintain the appearance of various materials exposed to environmental stress. Its molecular structure contains a piperidine ring with two hydroxyethyl groups and a tert-butyl group, providing the compound with its stabilizing properties. TERT-BUTYL 4,4-BIS(2-HYDROXYETHYL)PIPERIDINE-1-CARBOXYLATE is known for its ability to protect against the harmful effects of sunlight and heat, making it a valuable ingredient in the production of durable and long-lasting products.

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 189333-46-8 9-benzyl-2,4-dioxo-3,9-diazaspiro[5,5]undecane-1,5-dicarbonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1051383-60-8 diethyl 2,2'-(1-(tert-butoxycarbonyl)piperidine-4,4-diyl)diacetate 
• 160133-32-4 ethyl 2-[1-benzyl-4-(2-ethoxy-2-oxoethyl)-4-piperidyl]acetate 
• 160133-33-5 1-benzylpiperidine-4,4-diethanol 

Downstream Products

• 236406-47-6 3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester hydrochloride 
• 1225436-56-5 1-(9-(3,3-difluoroazetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4-methoxy-2,6-dimethylphenylsulfonyl)piperidin-2-yl)methoxy)ethanone 
• 1225436-57-6 1-[3-(3-fluorophenyl)-3-pyrrolidin-1-yl-9-azaspiro[5.5]undecan-9-yl]-2-[1-[[3-(trifluoromethyl)phenyl]sulfonyl]-piperidin-2-yl]-ethanone 
• 1225436-55-4 1-(9-(azetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4-methoxy-2,6-dimethylphenylsulfonyl)piperidin-2-yl)methoxy)ethanone 
• 1225437-13-7 tert-Butyl 9-(3-fluorophenyl)-9-(pyrrolidin-1-yl)-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225437-11-5 tert-Butyl 9-(3,3-difluoroazetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225437-01-3 tert-Butyl 9-(azetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225437-09-1 3-azaspiro[5.5]undecan-9-one hydrochloride 
• 1225437-12-6 9-(3,3-Difluoroazetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane 
• 873924-08-4 9-oxo-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester 

Relevant articles and documents

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

Substituted Spiroamine Compounds

Substituted spiroamine compounds corresponding to the formula (I) In which m, n, o, p, Q, r, s, t, R1, R2, R3, R4a, R4b, R5a, R5b, R6a, R6b, R7, R8, R9, R10 and R11 have defined meanings; a process for the preparation of such compounds, pharmaceutical compositions containing such compounds and the use of substituted spiroamines for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin 1 receptor.